

Pharmaceutical Benefits Advisory Committee

Email: PBAC@health.gov.au

Address all mail to:
PBAC Secretariat
GPO Box 9848
Canberra ACT 2601

DELISTING OF PHARMACEUTICAL BENEFIT ITEMS EFFECTIVE 01 NOVEMBER 2024

Following is the advice of the Pharmaceutical Benefits Advisory Committee (PBAC) concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act 1953*, with effect from the above date.

<u>Item</u>	<u>PBAC Advice</u>
Ribavirin	<p>The sponsor requested the delisting of Ibavyr[®] (ribavirin) from the Pharmaceutical Benefits Scheme (PBS).</p> <p>The PBAC noted the low number of services in the last financial year. The PBAC advised the delisting of this product would not result in an unmet clinical need.</p>

Vanessa McMahon
PBAC Secretary
Office of Health Technology Assessment
Technology Assessment and Access Division
24 October 2024